School of Medicine
Showing 11,741-11,750 of 12,379 Results
Adjunct Lecturer, Medicine - Med/Stanford Prevention Research Center
BioSandra J. Winter, PhD, MHA, is currently the Executive Director of Senior Coastsiders in Half Moon Bay, CA. Senior Coastsiders is a 501(c)3 nonprofit organization that has provided opportunities, support, and resources for older adults on the San Mateo Coast since 1977. Senior Coastsiders prepares meals that are served in the dining room or home delivered; provides information assistance and caregiver support; carries out minor repairs to improve home safety; facilitates transport to and from the center; and coordinates a variety of classes and activities. Sandi is an Adjunct Lecturer at the Stanford Prevention Research Center and a member of the Community Health and Prevention Research (CHPR) Master of Science Advisory Board.
Sandi was born and raised in Zimbabwe, then moved to Cape Town in South Africa where she was a successful entrepreneur, owning and operating a number of businesses in the advertising industry. In 2003 Sandra moved with her family from Cape Town, South Africa to Lexington, Kentucky where she completed a Master of Health Administration in May, 2006 and a PhD in Public Administration (Health Policy Track) in December, 2009 at the University of Kentucky. Her graduate research work focused on the health care that is provided to prison inmates in Kentucky.
In 2009 Sandra moved from Kentucky to California where she started working at the Stanford Prevention Research Center (SPRC). At SPRC Sandra held a number of positions including Fitness assessor, biometric screener and wellness advisor with the BeWell program; Social Science Research Assistant with Abby King’s Healthy Aging Research and Technology Solutions (HARTS) lab; Project Manager for the SPRC/Qassim University College of Medicine, Saudi Arabia collaboration, Postdoctoral Research Fellow with the National Heart Lung and Blood Institute and Director of the WELL for Life initiative.
Sandra's research areas of interest include wellbeing, community-based interventions among under resourced populations; reducing health disparities (particularly in a global context); the role the environments in which we live, work and play affect our ability to lead healthy active lives; and how we can use technology to encourage and support health behavior improvements.
Erin K. Wipff MSN, RN, ANP-BC
BioErin Wipff earned her Bachelors of Arts in Biology from University of California, Santa Cruz and Bachelors of Nursing from Johns Hopkins University. She received her Masters of Science in Nursing in Adult Primary Care with a minor in HIV from the University of California, San Francisco. She is board certified through the American Academy of Nurse Practitioners and a member of the California Association of Nurse Practitioners and Sigma Theta Tau. Her experience ranges from care of patients in the inpatient and outpatient settings with focuses in research, oncology, endocrinology, and neurosurgery. She currently supports the neurosurgical practice of Dr. Juan Fernandez-Miranda, Surgical Director of the Stanford Brain Tumor, Skull Base, and Pituitary Centers.
Paul H. Wise, MD, MPH
Richard E. Behrman, MD, Professor of Child Health and Society
Current Research and Scholarly InterestsHe is a health policy and outcomes researcher whose work has focused on children's health; health-outcomes disparities by race, ethnicity and socioeconomic status; the interaction of genetics and the environment as these factors influence child and maternal health; and the impact of medical technology on disparities in health outcomes.
Professor of Epidemiology and Population Health, of Biomedical Data Science and, by courtesy, of Genetics
BioDr. Witte joined the Stanford community in July 2021. In addition to serving as Vice Chair and professor in the Department of Epidemiology & Population Health, and as a professor of Biomedical Data Science and, by courtesy, of Genetics, he will also serve as a member of the Stanford Cancer Institute.
Dr. Witte is an internationally recognized expert in genetic epidemiology. His scholarly contributions include deciphering the genetic and environmental basis of prostate cancer and developing widely used methods for the genetic epidemiologic study of disease. His prostate cancer work has used comprehensive genome-wide studies of germline genetics, transcriptomics, and somatic genomics to successfully detect novel variants underlying the risk and aggressiveness of this common disease. A key aspect of this work has been distinguishing genetic factors that may drive increased prostate cancer risk and mortality among African American men. Providing an avenue to determine which men are more likely to be diagnosed with clinically relevant prostate cancer and require additional screening or specific treatment can help reduce disparities in disease prevalence and outcomes across populations. Dr. Witte has also developed novel hierarchical and polygenic risk score modeling for undertaking genetic epidemiology studies. These advances significantly improve our ability to detect disease-causing genes and to translate genetic epidemiologic findings into medical practice.
Dr. Witte has received the Leadership Award from the International Genetic Epidemiology Society (highest award), and the Stephen B. Hulley Award for Excellence in Teaching. His extensive teaching portfolio includes a series of courses in genetic and molecular epidemiology. He has mentored over 50 graduate students and postdoctoral fellows, serves on the executive committees of multiple graduate programs, and has directed a National Institutes of Health funded post-doctoral training program in genetic epidemiology for over 20 years. Recently appointed to the National Cancer Institute Board of Scientific Counselors, Dr. Witte has been continuously supported by the National Institutes of Health.
Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly Interests1) Amyloidosis -- Optimizing diagnosis/therapy and discovering new treatments
2) CardioOncology -- Understanding, treating, and preventing cancer therapy-induced cardiotoxicity
3) Sarcoidosis -- Exploring novel diagnostic modalities and determining optimal treatment, with a focus on cardiac sarcoidosis